Table 2 Comparison of treatments and prognoses

 Blood transfusion of RBC, n (%)

13 (29)

12 (50)

1 (5)

 Use of ESAs, n (%)

20 (44)

16 (67)

4 (19)

 Plasma exchange therapy, n (%)

6 (13)

6 (25)

0 (0)

 Steroid pulse therapy, n (%)

20 (44)

13 (54)

7 (33)

 Use of CY within 4 weeks after treatment initiation, n (%)

1 (2)

1 (4)

0 (0)

 Use of CY within 12 weeks after treatment initiation, n (%)

14 (35)

9 (47)

5 (24)

 Duration of hospitalization (days)

70 ± 26

75 ± 28

65 ± 23

 Number of deaths during the first hospitalization, n (%)

4 (9)

4 (17)

0 (0)

 Number of deaths at last follow-up, n (%)

11 (24)

8 (33)

3(14)

 Number of patients with end-stage kidney disease at last follow-up, n (%)

2 (4)

2 (8)

0 (0)